Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

Pickel, H; Petru, E; Lahousen, M; Stettner, H; Heydarfadai, M; Arian-Schad, K; Hackl, A.
Consolidation radiotherapy following carboplatin-based chemotherapy in radically operated advanced ovarian cancer. A pilot study.
Am J Clin Oncol. 1991; 14(3):184-187 Doi: 10.1097/00000421-199106000-00002
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Co-authors Med Uni Graz
Hackl Arnulf
Kapp Karin S.
Lahousen Manfred
Petru Edgar
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Adjuvant chemoradiotherapy was administered to 26 patients with stage Ic-IV ovarian cancer after radical cytoreductive surgery. All patients received six cycles of carboplatin, epirubicin, and prednimustine and had no evidence of disease after completion of chemotherapy. They received whole-abdominal radiation and radiation to the retroperitoneal lymph nodes. Five (23%) of the patients were discontinued on this protocol because of myelosuppression, progressive disease, or withdrawal. One patient had a small bowel obstruction due to intraperitoneal adhesions. The survival of 10 Stage III ovarian cancer patients who received chemoradiotherapy and were evaluable for assessment of treatment efficacy was retrospectively compared with the survival of 11 Stage III patients who received chemotherapy only. At 36 months, a slight advantage of the chemoradiotherapy versus the chemotherapy-only group was observed (p = 0.11). These preliminary results suggest that adjuvant chemoradiotherapy may prolong the "no evidence of disease" interval of radically operated ovarian cancer patients. Toxicity is acceptable when second-look surgery is avoided and when subsequent radiotherapy is limited to patients with no clinical evidence of disease.
Find related publications in this database (using NLM MeSH Indexing)
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carboplatin - administration & dosage
Carboplatin - therapeutic use
Combined Modality Therapy -
Epirubicin - administration & dosage
Female -
Hematologic Diseases - etiology
Humans -
Neoplasm Staging -
Ovarian Neoplasms - mortality
Ovarian Neoplasms - therapy
Pilot Projects -
Prednimustine - administration & dosage
Survival Rate -

Find related publications in this database (Keywords)
Advanced Ovarian Cancer
Sequential Chemoradiotherapy
Toxicity
Survival
© Med Uni GrazImprint